Profile data is unavailable for this security.
About the company
Shanghai Rightongene Biotechnology Co Ltd is a China-based company principally engaged in the research and development, production and sales of in-vitro diagnostic products, as well as the provision of scientific research and testing services. The Company's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The Company mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The Company also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The Company mainly conducts its businesses within domestic market.
- Revenue in CNY (TTM)265.52m
- Net income in CNY7.17m
- Incorporated2012
- Employees501.00
- LocationShanghai Rightongene Biotechnology Co Ltd#6055 Jinhai ExpresswayFengxian District, Building 3Shanghai 201403ChinaCHN
- Phone+86 2 133282601
- Fax+86 2 137199015
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dali Pharmaceutical Co Ltd | 65.70m | -22.85m | 1.09bn | 272.00 | -- | 2.91 | -- | 16.62 | -0.104 | -0.104 | 0.2991 | 1.71 | 0.1381 | 1.15 | 15.89 | 241,555.10 | -4.80 | -2.31 | -5.61 | -2.77 | 22.16 | 65.39 | -34.78 | -7.00 | 3.11 | -- | 0.0593 | -- | -34.06 | -26.30 | -13.16 | -- | 16.34 | -- |
| AVE Science & Technology Co Ltd | 206.22m | 24.46m | 1.17bn | 492.00 | 47.65 | 2.36 | -- | 5.65 | 0.3597 | 0.3597 | 3.03 | 7.28 | 0.3795 | 2.04 | 33.65 | 419,148.40 | 4.50 | 7.21 | 4.92 | 8.18 | 55.69 | 58.93 | 11.86 | 15.48 | 5.60 | -- | 0.00 | 22.46 | 1.79 | 5.88 | 19.81 | -4.62 | -23.68 | -- |
| Shanghai Rendu Biotechnology Co Ltd | 180.85m | -8.77m | 1.35bn | 528.00 | -- | 1.42 | -- | 7.49 | -0.2192 | -0.2192 | 4.52 | 23.78 | 0.1695 | 1.82 | 1.99 | 342,521.40 | -0.8215 | -- | -0.8869 | -- | 70.19 | -- | -4.85 | -- | 13.78 | -- | 0.008 | -- | 3.95 | -- | -63.89 | -- | -- | -- |
| Shaanxi Kanghui Pharmaceutical Co Ltd | 588.60m | -70.10m | 1.44bn | 828.00 | -- | 1.46 | -- | 2.44 | -0.7018 | -0.7018 | 5.89 | 9.84 | 0.289 | 2.23 | 3.02 | 710,868.00 | -4.51 | 1.41 | -6.35 | 1.71 | 30.41 | 45.74 | -15.60 | 4.48 | 0.8839 | -2.79 | 0.4034 | 32.34 | 11.01 | 6.01 | -272.84 | -- | 107.49 | -- |
| Shanghai Rightongene Biotechnlgy Co Ltd | 265.52m | 7.17m | 1.44bn | 501.00 | 194.10 | 1.55 | -- | 5.44 | 0.1332 | 0.1332 | 4.75 | 16.67 | 0.2540 | 1.09 | 1.40 | 529,970.30 | -0.0901 | 4.16 | -0.098 | 4.49 | 75.02 | 70.45 | -0.3548 | 11.62 | 10.43 | -- | 0.0284 | 5.90 | -39.14 | 2.84 | -80.41 | -11.46 | 19.65 | -- |
| Shanghai Serum Bio-Technology Co Ltd | 192.49m | 37.23m | 1.60bn | 321.00 | 42.96 | 1.47 | -- | 8.31 | 0.3441 | 0.3441 | 1.78 | 10.05 | 0.1689 | 0.9282 | 6.82 | 599,656.40 | 3.27 | 10.43 | 3.32 | 10.84 | 75.08 | 80.54 | 19.34 | 32.57 | 50.03 | -- | 0.0119 | 64.93 | 9.14 | 5.67 | -39.54 | -1.62 | 13.07 | -- |
| Shanghai Jiaoda Onlly Co Ltd | 280.54m | -39.86m | 1.72bn | 935.00 | -- | 5.90 | -- | 6.13 | -0.0514 | -0.0514 | 0.362 | 0.3761 | 0.3475 | 5.15 | 4.63 | 300,042.20 | -4.64 | -7.62 | -7.62 | -10.70 | 18.03 | 40.06 | -13.36 | -27.01 | 0.6301 | -1.40 | 0.3455 | -- | -21.43 | 2.65 | 92.96 | -- | -34.81 | -- |
| Guangzhou LBP Medicine Scnc&Tech Co Ltd | 508.01m | 40.23m | 1.73bn | 907.00 | 43.15 | 1.36 | -- | 3.41 | 0.4292 | 0.4292 | 5.32 | 13.61 | 0.3719 | 2.12 | 2.15 | 560,104.20 | 1.83 | 5.10 | 1.91 | 5.55 | 67.83 | 75.15 | 4.91 | 12.97 | 6.70 | -- | 0.0068 | 24.42 | -1.99 | 10.18 | -6.18 | -8.21 | -2.98 | -- |
Data as of May 17 2024. Currency figures normalised to Shanghai Rightongene Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
14.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 30 Jun 2023 | 2.96m | 8.06% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2023 | 881.57k | 2.40% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2023 | 347.95k | 0.95% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2023 | 331.85k | 0.90% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2023 | 267.12k | 0.73% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2023 | 250.00k | 0.68% |
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 120.20k | 0.33% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023 | 56.10k | 0.15% |
| Dongxing Asset Management Co. Ltd.as of 30 Jun 2023 | 41.92k | 0.11% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2023 | 13.67k | 0.04% |
More ▼
Data from 30 Jun 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
